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Summary T lymphocytes, activated by interleukin 2 during an anti-tumour response, release soluble interleukin 2 receptors (slL-2R) into the
bloodstream. We analysed the prognostic value of the serum slL-2R level in gastric cancer. Serum concentration of slL-2R in 96 gastric
cancer patients and 100 healthy control subjects' was measured by enzyme-linked immunosorbent assay. All survivors were followed for
more than 50 months. Serum slL-2R level was considered with respect to prognosis, clinicopathological factors, other tumour markers and
peripheral blood cell count. Stage IlIl and IV patients had significantly higher slL-2R levels than lower stage patients and control subjects.
Stage Ill and IV gastric cancer patients were divided into 'high' and 'low' slL-2R groups based upon the control subjects' serum slL-2R mean
value plus one standard deviation. The high group had a significantly worse prognosis than the low group, although clinicopathological
features and treatments were similar. Multivariate analysis demonstrated that the serum slL-2R level is an independent indicator. The sIL-2R
level did not correlate with carbohydrate antigen 19-9, however it did correlate with carcinoembryonic antigen (r= 0.22) and with numbers of
peripheral blood monocytes (r= 0.54). In conclusion, serum slL-2R may predict the outcome of gastric cancer patients with stage IlIl or IV
disease.
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Interleukin 2 (IL-2) plays an important role in the activation ofthe
host immune response (O'Garra, 1989). T lymphocytes are acti-
vated by the binding of IL-2 to membrane-bound IL-2 receptors
and they release the soluble IL-2 receptor (sIL-2R) into the blood
circulation (Rubin et al, 1985). It has been demonstrated that
T cells express three types of interleukin-2 receptor (IL-2R)
subunits, a low-affinity receptor (a-chain, p55, Tac antigen), an
intermediate-affinity receptor (,B-chain, p75) (Takeshita et al,
1989) and a y-chain (Takeshita et al, 1992). The combination of
the a- and a-chains constitute the high-affinity receptor
(Taniguchi and Minami, 1993). The soluble form of IL-2R is the
a-chain, which can bind to IL-2 in the blood with a similaraffinity
to the membrane-bound a-chain (Rubin et al, 1986).
High serum sIL-2R levels have been reported in patients with
adult T-cell leukaemia (Uchiyama et al, 1985), autoimmune
diseases (Symons et al, 1988), tuberculosis (Brown et al, 1989)
and viral hepatitis (Yamaguchi et al, 1988). Additionally, elevated
levels of serum sIL-2R have been reported in diverse solid
tumours including lung cancer (Buccheri et al, 1991; Poulakis et
al, 1991), nasopharyngeal cancer (Lai et al, 1991), breast cancer
(Sharma et al, 1991), Hodgkin's disease (Ambrosetti et al, 1993),
ovarian cancer (Barton et al, 1993, 1994; Gadducci et al, 1994),
colon cancer (Berghella et al, 1994; Murakami et al, 1994a) and
gastric cancer (Murakami et al, 1994b; Wang et al, 1994). To the
bestofourknowledge, however, there has been no published study
on the relationship between serum sIL-2R levels and the prognosis
ofpatients with gastric cancer. In this study, we analysed the prog-
nostic value ofserum sIL-2R in gastric cancer.
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PATIENTS AND METHODS
Patients
Ninety-six consecutive patients withhistologically proven primary
gastric carcinoma who underwent surgery between January 1992
and December 1992 at the First Department of Surgery, Osaka
City University Hospital, were studied. Peripheral blood samples
were obtained from each patient upon admission to the hospital
and, after centrifugation, the serum samples were stored at - 20°C
until assayed. Serum samples from 100 healthy individuals were
used as controls. There were no statistically significant differences
in age and sex between patients and healthy controls; mean
age ± SD, 58.2 ± 11.3 years vs 59.9 ± 10.9 years (P = 0.530);
male-female, 67:29 vs. 75:25 (P = 0.389). Patients who had
multiple cancers or any autoimmune disease were excluded from
this study. No patient received neoadjuvant chemotherapy or
irradiation. The patients with stage II to IV disease were given
5-fluorouracil orally after operation. All the pathological diag-
noses and classifications were made according to the Japanese
Classification of Gastric Carcinoma (Japanese Research Society
for Gastric Cancer, 1995). All surviving patients were followed for
more than 50 months. The survival period was defined as the
interval from when the serum sample was obtained until 28
February 1997 for all living patients or until the day ofdeath.
Assay
The sera were assayed for sIL-2R with an enzyme-linked
immunosorbent assay using Cellfree Interleukin 2 Receptor Kits
(Yamanouchi, Tokyo, Japan) according to the manufacturer's
instructions. In brief, a serum sample was added on a bead coated
with a monoclonal antibody which relates to one epitope of sIL-
2R. After incubation for 2 h, the sIL-2R fixed on the bead was
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reacted with horseradish peroxidase-conjugated monoclonal anti-
body, which binds a second epitope of sIL-2R. Following the sand-
wich assay, the colour reaction was terminated by addition of 2 N
sulphuric acid and the absorbance was measured at 492 nm. Our
reference value for sIL-2R was 639 U min' (the mean of 100 healthy
controls plus one standard deviation). Serum carcinoembryonic
antigen (CEA) levels and carbohydrate antigen 19-9 (CA 19-9)
levels were measured by counting immunoassay using a commer-
cially available CEA kit (Ranream CEA; TOA Medical Electronics,
Kobe, Japan) and a CA 19-9 kit (Ranream CA 19-9; Toray-Fuji
Bionics, Tokyo, Japan). The cut-off values of CEA and CA 19-9
levels recommended by the manufacturer were 6.5 ng ml' and
37 U ml1- respectively. Thewhitebloodcell, lymphocyte and mono-
cyte numbers were counted by a radio frequency/direct current
detection method using an automated haematology analyser
(SE-9000, TOA Medical Electronics, Kobe, Japan).
Statistical analysis
The non-parametric Mann-Whitney U-test was used for the
comparison of data between the two groups. The parametric
Student's t-test was used for the comparison of age between the
two groups. The survival data were estimated by the
Kaplan-Meier method andexamined by the log-ranktest. The Cox
proportional hazards model was employed for the multivariate
analysis of survival. The chi-square test was used to compare the
prevalence or distribution of two variables. The correlation
between the sIL-2R level and tumour marker orblood cell number
was assessed by linear regression using the least-squares method.
A P-value of< 0.05 was considered statistically significant.
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Figure 1 The distribution of the serum soluble interleukin-2 receptor (sIL-
2R) level according to stage of disease (I-IV), as defined in the Japanese
Classification of Gastric Carcinoma, and healthy control subjects (H). The
numbers in parentheses refer to the number of cases examined. There were
significant differences between the serum slL-2R levels of those with stage
III/IV disease and those with stage I/ll disease or the healthy control subjects
by Mann-Whitney L-test (P= 0.0002 or P= 0.0005 respectively). The
horizontal line represents the median value
RESULTS
Serum slL-2R level and clinicopathological features in
gastric cancer
The serum sLL-2R level in the patients with primary gastric cancer
was 502 ± 254 U ml-' (mean ± SD) with a median value of
443 U ml-' (range 173-1880 U ml-'). There was no statistically
significant difference between serum sIL-2R levels in all
patients with gastric cancer and in healthy control subjects
Table 1 Association between clinicopathological factors and the serum soluble interleukin-2 receptor level.
Features Number sIL-2R (U ml-1) P-value
Mean ± SD Median (range)
Histology
Differentiated type 44 503 ± 206 466 (173-1380) 0.386
Undifferentiated type 52 501 ± 290 438 (186-1880)
Peritoneal metastasis
Negative 88 476 ± 210 436 (173-1380) 0.012
Positive 8 792 ± 468 616 (362-18w)
Hepatic metastasis
Negative 90 483 ± 237 438 (173-1880) 0.022
Positive 6 782 ± 353 726(362-1380)
Serosal invasion
Negative 67 443 ±161 421 (186-929) 0.007
Positive 29 639 ±359 601 (173-1880)
Lymph node metastasis
nO,nl 78 475 ±186 422 (186-1040) 0.010
> n2 18 845±600 586 (173-1880)
Lymphatic invasion
1yO,lyl 66 446 ±162 416 (186-929) 0.015
>Iy2 30 626±358 579 (173-1880)
Venous invasion
vO,v1 86 466 ± 180 436 (186-1040) 0.011
> v2 10 812 ±502 720(173-1880)
Differentiated type includes papillary adenocarcinoma and well-differentiated and moderately differentiated tubular adenocarcinoma.
Undifferentiated type includes poorly differentiated adenocarcinoma, signet-nng cell carcinoma and mucinous carcinoma. The P-values were
determined by the Mann-Whitney L-test.
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Figure 2 Probability of survival for all stage gastric cancer patients in
relation to their serum slL-2R levels. The cut-off value between the high and
low serum slL-2R concentration was defined as 639 U ml-', which represents
the mean plus one standard deviation of the serum slL-2R concentration of
healthy control subjects. A statistically significant difference in survival rate
was observed between the high and low slL-2R groups
(mean + SD 509 + 130 U ml-1, median 442 U ml-' (range 277-
1220 U ml-'). However, the median sIL-2R level was significantly
higher in the stage III/IV gastric cancerpatients (mean + SD, 688 +
356 U ml-'; median 601 U ml-') than in those with stage 1/11
disease (mean ± SD 437 ± 164 U ml-', median 411 U ml-') or the
healthy control subjects (Figure 1). There was no significant
difference between the serum sIL-2R levels ofthose with differen-
tiated cancers (well-differentiated and moderately differentiated
tubular adenocarcinoma and papillary adenocarcinoma) and those
with undifferentiated cancers (poorly differentiated adeno-
carcinoma, signet-ring cell carcinoma and mucinous carcinoma).
However, there were significant differences in the serum sIL-2R
levels between those with and without serosal invasion, peritoneal
metastases and hepatic metastases. The serum sIL-2R level varied
with the extent oflymph node metastases as well as lymphatic and
venous invasion (Table 1).
Serum slL-2R level and prognosis in gastric cancer
When all patients with primary gastric cancer were divided into
high and low groups using a cut-off serum sIL-2R concentration of
639 U ml-', the high sIL-2R group consisted of 19 patients and the
low sIL-2R group consisted of 77 patients. The prognoses of the
two groups were significantly different (Figure 2). In those with
stage I/II disease, the prognoses ofthe high and low sIL-2R groups
were similar because only two patients in both groups died from a
recurrence of their disease. Conversely, there was a significant
difference in the prognoses of the two sIL-2R groups with stage
IIIJIV disease (Figure 3).
Nonetheless, the following clinicopathological features and
treatments for the two groups were not significantly different by
the chi-square test: stage III vs. IV, P = 0.23; differentiated type vs.
undifferentiated type, P = 0.09; peritoneal invasion negative vs.
positive, P = 0.91; hepatic metastasis negative vs. positive, P =
0.41; serosal invasion negative vs. positive, P = 0.10; lymph node
metastasis nO, nl vs. n2-n4, P = 0.91; lymphatic invasion lyO,lyl
vs. ly2,1y3, P = 0.06; venous invasion vO,vl vs. v2,v3, P = 0.51;
curability of gastric resection A (no residual tumours with high
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Figure 3 Probability of survival for stage III/IV gastric cancer patients in
relation to their serum slL-2R levels. The cut-off value between the high and
low serum slL-2R concentration was defined as 639 U ml-', which represents
the mean plus one standard deviation of the serum slL-2R concentration of
healthy control subjects. A statistically significant difference in survival rate
was observed between the high and low slL-2R groups
probability ofcure) vs. B (no residual tumours but not evaluated as
'Curability A') vs. C (definite residual tumours), P = 0.18.
Multivariate analysis for influence of the serum slL-2R
level on survival
Peritoneal, hepatic and lymph node metastases, depth ofinvasion,
lymphatic and venous invasion, serum sIL-2R, CEA and CA 19-9
level, and peripheral blood mononuclear cells (PBMCs) number
were analysed for all stage I-IV patients by the Cox proportional
hazards model. A high serum level sIL-2R was an independent and
strong factor which correlated with the prognosis ofpatients with
primary gastric cancer (Table 2).
Correlation of serum slL-2R level with CEA or CA 19-9
The sensitivity (the number of positive patients with gastric
cancer/the total number of patients with gastric cancer) of the
serum CEA and CA 19-9 concentrations in our series were 31.3%
and 6.3% respectively. The correlation coefficient values of the
sIL-2R level with the CEA and CA 19-9 levels were 0.22
(P = 0.03) and 0.09 (P = 0.37) respectively.
Correlation between the serum slL-2R level and
peripheral blood monocytes
There was a correlation between the serum sIL-2R level and the
number of PBMCs (r = 0.54, P < 0.0001) (Figure 4). However,
there was a weak or no correlation between the serum sIL-2R level
and the number of white blood cells (r = 0.20, P = 0.045) or
lymphocytes (r = 0.0004, P = 0.997).
DISCUSSION
Although there have been many studies on the serum sIL-2R level
in lung (Buccheri et al, 1991; Poulakis et al, 1991) and ovarian
cancer patients (Barton et al, 1993, 1994; Gadducci et al, 1994),
few studies have been reported on this cytokine receptor in the sera
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Figure 4 The linear regression analysis between the serum slL-2R titre and
the number of PBMCs. The two values were correlated
of gastric cancer patients. Lissoni et al (1990) found that
metastatic gastric cancer patients had significantly higher serum
sIL-2R levels than those with locally limited disease, and no
significant difference was observed when the patients were
grouped according to tumour histotype. Wang et al (1994) studied
the sera from 45 gastric cancer patients and concluded that the
mean sIL-2R level in gastric cancer patients was significantly
higher than that in healthy controls, and that patients with
metastatic disease had higher sIL-2R levels than those without
metastatic disease. Murakami et al (1994b) analysed the serum
sIL-2R levels of 40 patients with gastric cancer prior to surgery
and found that the status of lymph node metastasis alone signifi-
cantly influenced the serum sIL-2R level. We performed our study
using more subjects and obtained the following results: patients
with stage III/IV disease have elevated sIL-2R levels compared
with those with stage I/II disease and with healthy individuals.
There was no association between the histological type and the
serum sIL-2R level. There were significant differences in the
serum sIL-2R levels between the presence and the absence ofperi-
toneal metastasis, hepatic metastasis, serosal invasion, lymph node
metastasis, lymphatic invasion and venous invasion.
The mechanism responsible for the increase in the serum sIL-2R
level in patients with advanced solid tumours remains to be eluci-
dated. The serum sLL-2R level is thought to herald a surge of acti-
vated T cells (Rubin et al, 1985). If so, the increase in the sIL-2R
level may be the result of immune response activation. In contrast,
sIL-2R has been postulated to negatively modulate the host immune
response (Rubin and Nelson, 1990). When the sIL-2R concentration
increases inthe serum, itcompetes withthecell-surface1L-2receptor
for binding to IL-2 and it may reduce the availability ofIL-2 for IL-
2-dependent immune responses (Rubin et al, 1985). The possible
down-regulatory role of sIL-2R on T-cell function has not been
confirmed and it has been reported that even high concentrations of
sIL-2R are unable to block IL-2-induced T-cell proliferation in vitro
(Pizzolo et al, 1992). Although there havebeencontroversial reports,
the competition between sIL-2R and the cell-surface IL-2 receptor
may help to promote the growth of the primary tumour and any
metastases; therefore, the serum sIL-2R level may correlate with a
patient's prognosis. Buccheri et al (1991) reported that lung cancer
patients with elevated serum sIL-2R levels (> 700U ml-l, the 93rd
percentile value of healthy subjects) had a worse prognosis than
those who did not. From their analysis of 85 patients with head and
neck squamous cell carcinoma, Tartour et al (1997) suggested that
the serum sLL-2R level at the time ofdiagnosis can serve as an inde-
pendent prognostic indicator for the risk of locoregional recurrence
and survival. (Tartour et al, 1997). Our results in gastric cancer
patients were consistent with these previous reports. Patients with a
high sLL-2Rlevel (>639 Uml-') had asignificantly poorerprognosis
than those who did not. Furthermore, an elevated serum sIL-2R
concentration was a strong and independent predictorby multivariate
survival analysis for the prognosis ofpatients with gastric cancer.
CEA and CA 19-9 are two of the most useful tumour markers
for the diagnosis and monitoring of patients with gastric cancer.
These tumour-associated antigens are shed from the tumour cell
into the blood (Gold and Freedman, 1965; Koprowski et al, 1981).
Similarly, sIL-2R was initially postulated to be released from acti-
vated T cells during a host immune response (Rubin et al, 1985). It
has been reported that natural killer (NK) cells, activated B cells,
PBMCs and eosinophils also express the p55 receptor (sIL-2R)
(Waldmann et al, 1984; Holter et al, 1987; Rand et al, 1991).
Recently, it has been reported that various carcinoma cell lines
express the a- and 5-chains of IL-2R (Yasumura et al, 1994). In
Table 2 Multivariate analysis of independent prognostic indicators in gastric cancer patients by the Cox proportional hazards model
Variable Coefficient Standard error (P-value) 95% Cl Hazard ratio
Peritoneal metastasis 0.379 0.477 0.4266 0.574-3.723 1.461
Hepatic metastasis 1.375 0.514 0.0074 1.445-10.828 3.956
Depth of invasion 0.256 0.356 0.4720 0.643-2.596 1.292
Lymph node metastasis 1.657 0.425 < 0.0001 2.280-12.068 5.246
Lymphatic invasion 1.056 0.709 0.1365 0.716-11.534 2.874
Venous invasion -1.747 0.638 0.0062 0.050-0.609 0.174
Serum slL-2R level 2.342 0.841 0.0053 2.002-54.028 10.401
(> 639 U ml-')
Serum CEA level 0.322 0.835 0.6993 0.269-7.091 1.381
(> 6.5 ng ml-')
Serum CA 19-9 level 1.920 0.960 0.0456 1.038-44.784 6.818
(> 37 U ml-')
PBMC number (> 562 mm-3) 0.102 0.979 0.9169 0.163-7.546 1.108
CEA, carcinoembryonic antigen; CA 19-9, carbohydrate antigen 19-9; PBMC, peripheral blood mononuclear cell. The cut-off values were the means plus one
standard deviation of healthy controls forslL-2R and PBMCs, and the levels recommended by the manufacturers of the assay kits for CEA and CA 19-9.
British Journal of Cancer (1998) 77(11), 1820-1824 0 Cancer Research Campaign 19981824 B Nakata etal
our study, the serum levels of sIL-2R were elevated according to
the extent ofthe gastric tumour, raising the possibility that sIL-2R
was produced by the tumour cells. However, the release of sIL-2R
into the circulation from the carcinoma itself has not been firmly
proven. Perhaps because of these differences in release, there was
no, or only a weak, correlation between the serum sIL-2R level
and the serum CA 19-9 or CEA concentration in those patients
with gastric cancer. Thus, the serum sIL-2R concentration can be
used as an alternative tumour marker in those with gastric cancer.
We recognized an association between the serum sIL-2R
concentration and the PBMCs. The correlation can be explained in
at least two ways. The first is that the increased PBMCs them-
selves release high levels of sIL-2R in the serum, while the second
is that the increased PBMCs stimulate a lot of T cells, which shed
much sIL-2R (Rubin et al, 1985). In any event, the PBMCs tended
to be higher in patients with a high serum sIL-2R level. In contrast,
the number of lymphocytes or white blood cells did not correlate
with or correlated weakly with the serum sIL-2R concentration
because these cell counts may not be affected by activated T cells
or other immunoregulatory cells which release sIL-2R.
In conclusion, serum sIL-2R may be an independent prognostic
indicator for patients with gastric cancer, especially those with
advanced-stage disease. Further studies must address the question
as to whether carcinoma cells themselves can release sIL-2R into
the serum.
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